Intact Vascular
Series D in 2019
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.
Vesper Medical
Venture Round in 2019
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.
Keep patients more informed and engaged in the emergency room, hospital, and beyond. Vital’s AI-powered patient experience solutions give patients control, clarity, and predictability when they need it most.
Intact Vascular
Series C in 2018
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.
TELA Bio
Private Equity Round in 2017
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.
Intact Vascular
Series B in 2017
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.
Intact Vascular
Series B in 2015
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.
Rapid Micro Biosystems
Series C in 2015
Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.
Tarsa Therapeutics
Series B in 2014
Tarsa Therapeutics, Inc. is focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases, particularly in postmenopausal women. The company is advancing TBRIA, an oral formulation of salmon calcitonin, which aims to slow the rate of bone destruction associated with osteoporosis. Tarsa Therapeutics provides clinical programs that address both the treatment and prevention of osteoporosis, specifically targeting women who are more than five years post-menopause and may not be suitable for alternative therapies. Founded in 2009 and based in Philadelphia, Pennsylvania, Tarsa Therapeutics was previously known as Boneco, Inc.
Rapid Micro Biosystems
Venture Round in 2014
Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.
Rapid Micro Biosystems
Series B in 2013
Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.
Regado Biosciences
Series E in 2012
Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.
Corridor Pharmaceuticals
Series A in 2009
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Neuronetics
Series C in 2006
Neuronetics, Inc. is a commercial stage medical technology company that specializes in developing non-invasive therapies for psychiatric disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company markets the NeuroStar Advanced Therapy System, which provides a non-invasive treatment for adults suffering from major depressive disorder. This system employs transcranial magnetic stimulation (TMS) to generate a pulsed, MRI-strength magnetic field that induces electrical currents aimed at stimulating specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team targeting psychiatrist customers, focusing on improving the quality of life for individuals with mental health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.